QTTB vs AKRO vs IMVT vs ARQT vs CABA

Q32 Bio Inc.

(QTTB) offers the better valuation at 5. 2x trailing P/E, making it the more compelling value choice. Analysts rate Akero Therapeutics, Inc. (AKRO) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +207. 0%, compared to -90. 2% for Q32 Bio Inc. (QTTB). Over 10 years, the gap is even starker: IMVT returned +230. 5% versus QTTB's -96. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Akero Therapeutics, Inc.

(AKRO) is the lower-risk stock at 0. 35β versus Cabaletta Bio, Inc. 's 2. 18β — meaning CABA is approximately 530% more volatile than AKRO relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 37% for Q32 Bio Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Q32 Bio Inc.

grew EPS 136. 8% year-over-year, compared to -29. 8% for Akero Therapeutics, Inc.. Over a 3-year CAGR, ARQT leads at 367. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Q32 Bio Inc.

(QTTB) is the more profitable company, earning 55. 5% net margin versus -4. 3% for Arcutis Biotherapeutics, Inc. — meaning it keeps 55. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: QTTB leads at 31. 5% versus -3. 3% for ARQT. At the gross margin level — before operating expenses — QTTB leads at 99. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for CABA: 442.

5% to $16. 33.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Akero Therapeutics, Inc.

(AKRO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 35), +198. 3% 10Y return). Cabaletta Bio, Inc. (CABA) carries a higher beta of 2. 18 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AKRO: +198. 3%, CABA: -69. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: QTTB is a small-cap deep-value stock; AKRO is a small-cap quality compounder stock; IMVT is a small-cap quality compounder stock; ARQT is a small-cap high-growth stock; CABA is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.